The global Clinical Mass Spectrometry Market is estimated to be valued at US$ 6.37 or Billion in 2023 and is expected to exhibit a CAGR of 6.2% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Clinical mass spectrometry is used widely in clinical settings for identification of infectious agents, metabolic profiling of tissues and fluids, drug testing and quantitation, and biomarker discovery and quantification. It provides real-time clinical diagnosis and treatment at point-of-care.
Market key trends:
One of the key trends in the clinical mass spectrometry market is growing adoption of mass spectrometry techniques for microbial identification. Early and accurate identification of microbial pathogens is crucial for the effective clinical management of infections. Mass spectrometry-based proteomic and genomic approaches offer rapid, sensitive, and specific identification of microbes directly from clinical specimens without requiring culture. This helps clinicians to optimize antimicrobial therapy and improve patient outcomes.
The global clinical mass spectrometry market is segmented as technology, application and end user. Based on technology, triple quadrupole segment held largest market share in 2022 attributed to its advantages such as high sensitivity, reproducibility, reliability, and simultaneous analysis of multiple analytes by MRM/MRM methods. The segment is expected to remain dominant during the forecast period due to the growing application of triple quadrupole for targeted quantitative analysis in proteomics, metabolomics, and other clinical applications.
The global clinical mass spectrometry market is expected to witness high growth, exhibiting CAGR of 6.2% over the forecast period, due to increasing demand for clinical mass spectrometry instruments from research laboratories and hospitals.
Regionally, North America accounted for largest share in the global clinical mass spectrometry market in 2022 and is projected to remain dominant during the forecast period. Increasing funding for research activities, presence of key market players, adoption of advanced mass spectrometry techniques are some factors attributed to its dominance. Asia Pacific region is expected to grow at fastest CAGR over the forecast period owing to rising healthcare expenditure, increasing research initiatives by pharmaceutical companies, and growing collaborations between industries and academic & research institutes.
Key players operating in the clinical mass spectrometry market are Agilent Technologies, Bruker Corporation, Danaher Corporation, Leco Corporation, Perkin Elmer Inc., Shimadzu Corporation, Thermo Fisher Scientific. Major players are focusing on new product launch, geographical expansion and collaboration & partnership strategies to gain market share and strengthen their geographic presence in the market. For instance, in 2022, Thermo Fisher Scientific collaborated with Proteona to deliver scalable proteomics workflows for mass spectrometry and accelerate translational research.